Pharmaceutical firm Cadila Healthcare today announced that it has received USFDA approval to conduct clinical trials for ZYGK1, a new molecular entity (NME), for treating diabetes.
Cadila Healthcare said the new molecular entity (NME) being designed and developed at the company’s research centre, is a potent and orally administered small molecule glucokinase activator.
The company will now initiate phase I clinical trials for ZYGK1, it said in a statement.
The company said in multiple preclinical models of Type 2 diabetes, ZYGK1 was found to be effective in controlling both fasting and non-fasting blood glucose.
ZYGK1 showed very good safety profile in preclinical studies, it said.
Head quartered at Ahmedabad, Gujarat, Cadila Healthcare is the fifth largest pharmaceutical company in India.